Before I start, don’t forget my deal of the day! Today back by popular demand I have the TradeKing deal. Also, don’t forget if you have to make any type of purchase from Amazon simply follow my link here, any purchase will help GekkoWire out and there are no extra charges to you, just a simple click on a link!!!!
Get $50 when you open a TradeKing account today. » Read more: Epicept Corporation (EPCT): Victim of FDA Politics? What all Cancer Company Investors Need to Know
Cell Therapeutics said this morning that the EMEA has validated their Pediatric Investigation Plan for their lead product Pixantrone in NHL patients. Pediatric Investigation Plans (PIPs) were made by the European Commission to help ensure that medicines for children are included in drug development programs, rather than a simple bolt-on process to adult studies. The PIP is part of a mandatory new portion of the Marketing Application in Europe designed so that companies develop drugs for children as well in properly run clinical trials. » Read more: Daily Pharma Watch
Alright pharma investors time a brief snippet on Cell Therapeutics, but before I start I would also like to let you that I will be doing what I call the “Deal of the Day.” This is where I partner with an affiliate to bring you a deal that you can’t get elsewhere, I have tons of great coupons at my fingertips, » Read more: Cell Therapeutics (CTIC) Tries to Increase Authorized Shares in Proxy Filing
Sunesis Pharmaceuticals (SNSS):
Zacks Premium FULL ACCESS Membership – 30-day free trial
So investors in Sunesis have finally gotten some word on the progress of the Phase III trial of voreloxin in AML patients. The company said this morning that they have put together a Steering Committee and other partners for the Phase III trial of the drug. The company also noted that the drug will now be called vosaroxin as accepted by the United States Adopted Names Council. » Read more: Daily Pharma Watch
So I have gotten a lot of questions about whether or not I think Cell Therapeutics will effect a reverse stock split or if they will need to raise capital. So per my last post back at the beginning of July I briefly went through their financing situation. Here it is: » Read more: Cell Therapeutics (CTIC) : Financing Options Ahead
This morning Cell Therapeutics said that they were able to raise another $4.06 million in capital in a preferred stock offering. The preferred stock will be convertible into 11.6 million shares of common stock. The company also said that they have came to an agreement with another investor to exchange existing warrants for new warrants at a lower exercise price. » Read more: Cell Therapeutics (CTIC) Raises More Captial
Daily Pharma Watch
Today is the big day for Vivus, they will meet with an advisory panel to discuss their lead product Qnexa. I am expecting a decision to come out around 1:30-2:00 pm. The only real thing investors can do now is wait and see what happens, trading in the stock is halted, but should resume after the announcement or tomorrow. » Read more: Daily Pharma Watch
Curis Inc. (CRIS):
This morning Curis announced that they will receive a $3 million milestone payment from Debiopharm for achieving the treatment of 5 patients with the drug Debio 932, also known as CUDC-305. CUDC-305 is being developed as a heat shock protein 90, or Hsp90, inhibitor. Hsp90 is a molecular chaperone protein that plays a role in cell signaling and it is believed that Hsp90 plays a significant role in the proliferation of cancer cells. In August 2009, Curis granted an exclusive royalty-bearing license to our Hsp90 inhibitor technology, including CUDC-305 to Debiopharm S.A., a Swiss pharmaceutical development company. » Read more: Daily Pharma watch
Cell Therapeutics (CTIC): Conference Call Rundown
Today Cell Therapeutics announced that they finally paid back their $39.3 million in convertible debt that was hanging over the company’s head. The move is a net positive for the company as several news outlets had been reporting prior to the payment that the company faced severe short-term funding issues. According to their latest filing the company had approximately $54 $69.7million of cash in the coffers before paying back the $39 million (filing here). » Read more: Cell Therapeutics (CTIC): Conference Call Rundown
Cell Therapeutics (CTIC):
Surprisingly there has been very little said about Cell Therapeutics out of the usual news outlets, so I am going to do a brief rundown of their finances. Cell Therapeutics said late yesterday that they were going to have to suspend their Annual Shareholder meeting for the final time in recent months. The company has noted that they will hold an Annual Meeting of shareholders later this year. » Read more: Cell Therapeutics (CTIC): Update on the Firm
© 2010 GekkoWire · Proudly powered by WordPress & Green Park 2 by Cordobo.
Valid XHTML 1.0 Transitional | Valid CSS 3
Twitter